Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 3/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 3/20 | 0.33 |
| ▸ | MMP14 | P50281 | 3/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.32 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22198690 | 0.84 | KMT2A (0.36) | MMP9MMP13MMP1MMP8MMP14 | |
| SCHEMBL30335840 | 0.80 | — | — | |
| SCHEMBL19537450 | 0.77 | — | — | |
| SCHEMBL20715339 | 0.74 | POLB (0.30) | POLB | |
| SCHEMBL25905688 | 0.74 | CYP2D6 (0.33) | MMP9MMP13MMP1CYP2D6HRH3 | |
| SCHEMBL20103556 | 0.73 | CYP3A4 (0.37) | — | |
| SCHEMBL19169447 | 0.73 | — | — | |
| SCHEMBL23324538 | 0.71 | MMP9 (0.32) | MMP9MMP13MMP1MMP8MMP14 | |
| SCHEMBL12026459 | 0.70 | L3MBTL1 (0.40) | KCNH2 | |
| SCHEMBL27425090 | 0.70 | HRH3 (0.42) | MMP9MMP13MMP1MMP8MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | MMP9 1838/4885MMP13 893/4885MMP1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.